Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer.

Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer. - Multicenter Randomized Phase II Study of consecutive-day versus alternate-day treatment with S-1 as Second-line chemotherapy in advanced pancreatic cancer. (SCOTCH)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009695

Enrollment

200

Registered

2013-01-04

Start date

2016-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

anti-cancer drug anti-cancer drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study is designed to enroll patients with unresectable,pathologically proven,pancreatic cancer.All patients is received initial treatment that includes an anti-cancer agent S-1 + other or other non S-1 for unresectable advanced pancreatic cancer.Other eligibility criteria includes performance status of 0-2,cases can be taken orally.Written informed consent is required from all patients.

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows active infection.Pregnant or lactating women,women of childbearging age.The patient inappropriate for entry onto this study in the judgment of the investigator.

Design outcomes

Primary

Measure	Time frame
Overall survival time	—

Secondary

Measure	Time frame
QOL,Progression-free survival,Time to treatment failure,Response rate, Frequency and severity of adverse events,	—

Countries

Japan

Contacts

Public ContactYoshiki Hirooka

Nagoya University Hospital Department of Endoscopy

jur16@med.nagoya-u.ac.jp052-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026